Sergio and David discuss the current landscape of longevity companies integrating into the regulatory and investment environment, with a focus on developing next generation interventions that can be deployed in humans. The influx of VC funding and big funds is propelling the longevity space forward, bringing us closer to the Holy Grail of longevity products.
